Recursion Pharma Files Routine 8-K; No Major Changes Reported
Ticker: RXRX · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1,000, $25,000, $15,000, $2,500 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, routine-filing
TL;DR
**Recursion Pharma filed a standard 8-K with no major news, suggesting business as usual.**
AI Summary
Recursion Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 6, 2024. This filing is a standard current report under the Securities Exchange Act of 1934, indicating no major changes in leadership, compensatory arrangements, or other significant corporate events that would typically be detailed in an 8-K. For investors, this matters because the absence of specific disclosures about 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' suggests business as usual, which can be a neutral signal for stock stability.
Why It Matters
This routine 8-K filing indicates no immediate significant corporate changes, providing a neutral signal for investors regarding the company's operational stability.
Risk Assessment
Risk Level: low — The filing is routine and does not disclose any events that would typically introduce new risks or uncertainties for the company.
Analyst Insight
A smart investor would note the routine nature of this 8-K, indicating no immediate red flags or catalysts, and would continue to monitor for more substantive filings or news regarding Recursion Pharmaceuticals, Inc.'s drug development pipeline or financial performance.
Key Numbers
- $0.00001 — par value per share (par value of Class A Common Stock)
Key Players & Entities
- RECURSION PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- February 6, 2024 (date) — date of the earliest event reported
- February 7, 2024 (date) — date the 8-K was filed
- 001-40323 (other) — Commission File Number
- RXRX (other) — Trading symbol for Class A Common Stock
- Nasdaq Global Select Market (other) — exchange where Class A Common Stock is registered
FAQ
What is the primary purpose of this 8-K filing by Recursion Pharmaceuticals, Inc.?
This 8-K filing is a 'Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934' and is a routine disclosure, specifically referencing 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' as the item information, though no specific events under these categories are detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 6, 2024, as stated in the 'Date of Report (Date of earliest event reported): February 6, 2024' section.
What is the trading symbol and exchange for Recursion Pharmaceuticals, Inc.'s Class A Common Stock?
The trading symbol for Recursion Pharmaceuticals, Inc.'s Class A Common Stock is RXRX, and it is registered on the Nasdaq Global Select Market.
What is the state of incorporation for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. is incorporated in Delaware, as indicated by 'Delaware (State or other jurisdiction of incorporation)' in the filing.
Does this 8-K filing indicate any changes in the company's executive leadership or compensation arrangements?
While the 'ITEM INFORMATION' section lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', the provided text of the 8-K does not detail any specific changes or events under these categories, suggesting it's a placeholder or a routine filing without specific new disclosures in these areas.
Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2024-02-07 16:56:26
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
- $1,000 — der the advisory agreement at a rate of $1,000 per hour (but with the amount of such f
- $25,000 — the amount of such fees being at least $25,000 for each month from February through Ju
- $15,000 — from February through July and at least $15,000 for each month from August through Dece
- $2,500 — e advisory agreement, a cash payment of $2,500; and if the Company terminates the agr
- $390,000 — reement is terminated, beginning with a $390,000 payment if terminated in February 2024,
- $65,000 — ted in February 2024, and decreasing by $65,000 per month thereafter. The foregoing de
Filing Documents
- rxrx-20240206.htm (8-K) — 24KB
- 0001601830-24-000012.txt ( ) — 147KB
- rxrx-20240206.xsd (EX-101.SCH) — 2KB
- rxrx-20240206_lab.xml (EX-101.LAB) — 23KB
- rxrx-20240206_pre.xml (EX-101.PRE) — 12KB
- rxrx-20240206_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on February 7, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer